Big pharma, Biotech, Partnering, Pharma

Merck and Newlink ink Ebola vaccine deal

Posted on 25 November 2014

Tags: , , ,

Merck and NewLink Genetics have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.

Merck will be granted the exclusive rights to the rVSV-EBOV vaccine candidate as well as any follow-on products.

The vaccine candidate is under an exclusive licensing arrangement with a wholly-owned subsidiary of NewLink Genetics.

Under these license arrangements, the PHAC retains non-commercial rights pertaining to the vaccine candidate.

For further deal information visit Current Agreements (subscription required)

Related

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

Print Friendly, PDF & Email

Leave a Reply